\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ notable\\ only\\ for\\ bilateral\\ conjunctivitis\\ and\\ conjunctival\\ hemorrhage\\ and\\ swelling\\ \ \(0\)\
\-\ lab\\:\ \(0\)\
\-\ no\\ abnormal\\ findings\ \(3\)\
\-\ the\\ patient\\ is\\ currently\\ being\\ followed\\ by\\ hematology\\/oncology\\.\\ \\ treatment\\ plan\\ currently\\ pending\\ further\\ bone\\ marrow\\ biopsy\\ confirmation\\ of\\ current\\ diagnosis\\.\ \(0\)\
\-\ head\\ ct\\:\\ bilateral\\ lacrimal\\ gland\\ enlargement\\ with\\ homogenous\\ tissue\\ attenuation\\.\\ \\ multiple\\ lucenies\\ of\\ the\\ skull\\ bilaterally\\,\\ particularly\\ posterior\\ to\\ the\\ vertex\\ ranging\\ 5\\-9\\ mm\\ in\\ size\\.\\ \\ diffuse\\ soft\\ tissue\\ attenuation\\ noted\\ in\\ right\\ maxillary\\ sinus\\ consistent\\ with\\ sinusitis\\.\\ \\ \\ \\ \ \(0\)\
\-\ skeletal\\ survey\\:\\ left\\ upper\\ extremity\\-single\\ round\\,\\ punched\\-out\\ appearing\\ lucencies\\ in\\ the\\ region\\ of\\ the\\ radial\\ tuberosity\\ and\\ proximal\\ humerus\\;\\ pa\\-chest\\-single\\,\\ round\\,\\ punched\\ out\\ appearing\\ lucency\\ in\\ the\\ lateral\\ left\\ clavicle\\;\\ skull\\-numerous\\,\\ round\\,\\ punched\\-out\\ appearing\\ lucencies\\ over\\ the\\ parietal\\ and\\ frontal\\ bones\\.\ \(0\)\
\-\ multiple\\ myeloma\\ \\ \\ and\\ secondary\\ amyloidosis\\ and\\ history\\ of\\ sarcoidosis\ \(0\)\
\-\ multiple\\ myeloma\ \(25\)\
\-\ osteolytic\\ metastatic\\ carcinoma\ \(0\)\
\-\ hyperparathyroidism\ \(35\)\
\-\ 46\\ year\\-old\\ woman\\ with\\ history\\ of\\ sarcoidosis\\,\\ anemia\\,\\ hypertension\\,\\ and\\ carpal\\ tunnel\\ syndrome\\ with\\ complaint\\ of\\ intermittent\\ bilateral\\ conjunctival\\ inflammation\\ and\\ hemorrhage\\ for\\ one\\ year\\.\\ \\ she\\ was\\ initially\\ seen\\ by\\ opthalmology\\ who\\ diagnosed\\ and\\ treated\\ her\\ for\\ conjunctivitis\\ associated\\ with\\ bilateral\\ lacrimal\\ gland\\ enlargement\\ demonstrated\\ on\\ numerous\\ ct\\ studies\\ of\\ the\\ orbits\\.\\ \\ she\\ was\\ diagnosed\\ with\\ sarcoidosis\\ thirteen\\ years\\ prior\\ via\\ bronchoscopy\\ and\\ maintains\\ that\\ she\\ has\\ remained\\ asymptomatic\\.\\ \\ she\\ also\\ has\\ bilateral\\ upper\\ extremity\\ paresthesias\\ that\\ are\\ diffuse\\ but\\ most\\ notable\\ in\\ the\\ ulnar\\ nerve\\ distribution\\ of\\ both\\ the\\ right\\ and\\ left\\ hands\\ and\\ she\\ has\\ been\\ diagnosed\\ with\\ bilateral\\ carpal\\ tunnel\\ syndrome\\ in\\ the\\ past\\ year\\.\\ \\ she\\ presents\\ with\\ no\\ other\\ complaints\\ and\\ review\\ of\\ systems\\ is\\ negative\\ for\\ constitutional\\,\\ cardiopulmonary\\,\\ gastrointestinal\\,\\ genitourinary\\,\\ or\\ musculoskeletal\\ complaints\\.\\ \\ her\\ most\\ recent\\ head\\ ct\\ was\\ obtained\\ during\\ evaluation\\ of\\ uri\\ symptoms\\ and\\ pain\\ over\\ the\\ right\\ maxillary\\ sinus\\,\\ for\\ which\\ she\\ was\\ diagnosed\\ with\\ sinusitis\\.\ \(0\)\
\-\ this\\ is\\ a\\ case\\ of\\ a\\ 46\\ year\\-old\\ black\\ female\\ with\\ a\\ history\\ of\\ sarcoidosis\\ diagnosed\\ at\\ age\\ 32\\ years\\,\\ and\\ bilateral\\ carpal\\ tunnel\\ syndrome\\ diagnosed\\ within\\ the\\ past\\ year\\ now\\ presenting\\ with\\ mulitple\\ myeloma\\.\\ \\ multiple\\ myeloma\\ \\(mm\\)\\ is\\ a\\ monoclonal\\ b\\-cell\\ malignancy\\ consisting\\ of\\ terminally\\ differentiated\\ plasma\\ cells\\.\\ \\ in\\ the\\ united\\ states\\,\\ the\\ incidence\\ of\\ disease\\ is\\ 3\\-4\\ newly\\ diagnosed\\ cases\\ per\\ 100\\,000\\ population\\ per\\ year\\,\\ and\\ represents\\ 1\\%\\ of\\ all\\ malignancies\\.\\ \\ demographically\\,\\ patients\\ are\\ commonly\\ african\\-american\\,\\ with\\ males\\ slightly\\ outnumbering\\ females\\ by\\ 1\\.4\\-1\\.\\ \\ patients\\ are\\ typically\\ elderly\\ with\\ a\\ median\\ age\\ of\\ 65\\ years\\ at\\ diagnosis\\,\\ although\\ cases\\ in\\ much\\ younger\\ patients\\ have\\ been\\ reported\\.\ \(0\)\
\-\ the\\ patient\\'s\\ presentation\\ for\\ mm\\ is\\ unusual\\ given\\ her\\ relatively\\ young\\ age\\ \\(46\\ years\\)\\,\\ lack\\ of\\ physical\\ findings\\ and\\ history\\ \\(i\\.e\\.\\ fatigue\\,\\ bone\\,\\ recurrent\\ infections\\)\\,\\ and\\ laboratory\\ abnormalities\\ \\(i\\.e\\.\\ hypercalcemia\\,\\ elevated\\ creatinine\\,\\ elevated\\ total\\ protein\\)\\ suggestive\\ of\\ \\ mm\\.\\ \\ the\\ bilateral\\ lacrimal\\ gland\\ amyloidosis\\ is\\ a\\ \\ unusual\\ initial\\ presentation\\ for\\ mm\\.\\ \\ by\\ comparison\\,\\ lacrimal\\ gland\\ involvement\\ in\\ sarcoidosis\\ is\\ more\\ common\\ affecting\\ 55\\-61\\%\\ of\\ patients\\ at\\ sometime\\ during\\ their\\ disease\\ course\\ with\\ similar\\ findings\\ on\\ ct\\ imaging\\.\\ \\ therefore\\,\\ her\\ management\\ was\\ based\\ on\\ the\\ conclusion\\ her\\ presentation\\ was\\ a\\ manifestation\\ of\\ her\\ sarcoidosis\\ and\\ not\\ mm\\.\\ \\ the\\ lack\\ of\\ response\\ to\\ therapy\\ for\\ the\\ lacrimal\\ gland\\ enlargement\\ ultimately\\ prompted\\ a\\ biopsy\\ of\\ the\\ gland\\ six\\ months\\ from\\ the\\ time\\ she\\ sought\\ medical\\ attention\\,\\ and\\ one\\ year\\ since\\ she\\ reported\\ initially\\ having\\ symptoms\\.\\ \ \(0\)\
\-\ the\\ lacrimal\\ gland\\ biopsy\\ showed\\ an\\ inflamatory\\ cell\\ infiltrate\\,\\ with\\ nodules\\ of\\ pauci\\-cellular\\,\\ eosinophillic\\ staining\\ material\\ exhibiting\\ apple\\-green\\ birefringence\\ on\\ congo\\ red\\ staining\\.\\ \\ this\\ is\\ consistent\\ with\\ amyloidosis\\ of\\ the\\ lacrimal\\ gland\\.\\ \\ the\\ lack\\ of\\ evidence\\ of\\ granulomatous\\ disease\\ present\\ in\\ the\\ biopsy\\ specimen\\ strongly\\ suggests\\ that\\ sarcoidosis\\ is\\ not\\ the\\ etiology\\ of\\ her\\ lacrimal\\ gland\\ enlargement\\.\\ \\ \ \(0\)\
\-\ based\\ on\\ the\\ above\\ findings\\,\\ the\\ patient\\ received\\ further\\ laboratory\\ and\\ radiological\\ investigations\\ for\\ the\\ diagnosis\\ of\\ mm\\.\\ \\ \\ the\\ diagnosis\\ of\\ mm\\ is\\ based\\ on\\ the\\ demonstration\\ of\\ three\\ components\\:\\ 1\\)\\ serum\\ or\\ urine\\ monoclonal\\ protein\\ identified\\ by\\ a\\ characteristic\\ monoclonal\\ m\\ protein\\ spike\\ on\\ electrophoresis\\ of\\ urine\\ and\\ blood\\ specimens\\;\\ 2\\)\\ \\>10\\%\\ abnormal\\ plasma\\ cells\\ on\\ bone\\ marrow\\ biopsy\\;\\ and\\ 3\\)\\ end\\-organ\\ damage\\ in\\ the\\ form\\ of\\ hypercalcemia\\,\\ renal\\ insufficiency\\,\\ sequelae\\ of\\ amyloid\\ deposition\\,\\ and\\/or\\ bone\\ abnormalities\\ on\\ imaging\\.\\ \\ most\\ patients\\ will\\ demonstrate\\ symptomatic\\ sequelae\\ of\\ of\\ end\\-organ\\ damage\\.\\ \\ however\\,\\ nearly\\ 25\\%\\ of\\ patients\\ with\\ mm\\ are\\ discovered\\ through\\ incidental\\ findings\\ on\\ laboratory\\ studies\\ and\\ imaging\\.\\ indeed\\,\\ radiographs\\ provided\\ the\\ only\\ significant\\ finding\\ suggestive\\ of\\ mm\\ via\\ a\\ head\\ ct\\ that\\ was\\ obtained\\ for\\ the\\ evaluation\\ of\\ uri\\ symptoms\\ of\\ sinusitis\\ in\\ an\\ emergency\\ department\\ several\\ months\\ prior\\ to\\ the\\ lacrimal\\ gland\\ biopsy\\.\\ \\ \ \(0\)\
\-\ the\\ characteristic\\ radiological\\ feature\\ of\\ mm\\ is\\ the\\ presence\\ of\\ a\\ single\\ osteolytic\\ lucency\\ \\(plasmacytoma\\)\\,\\ or\\,\\ as\\ in\\ this\\ patient\\'s\\ case\\,\\ multiple\\ discrete\\ osteolytic\\ lucencies\\ \\(myelomatous\\)\\ that\\ are\\ subcortical\\ and\\ found\\ predominantly\\ in\\ the\\ axial\\ and\\ proximal\\ appendicular\\ skeleton\\.\\ \\ lesions\\ may\\ also\\ coalesce\\ or\\ take\\ the\\ form\\ of\\ diffuse\\ osteopenia\\.\\ \\ sclerosing\\ myeloma\\ has\\ also\\ been\\ described\\,\\ although\\ it\\ is\\ rare\\.\\ \\ the\\ osteolysis\\ of\\ mm\\ is\\ mediated\\ by\\ the\\ secretion\\ of\\ chemokine\\ factors\\ by\\ the\\ malignant\\ plasma\\ cells\\ that\\ stimulate\\ osteoclast\\ proliferation\\,\\ chemotaxis\\,\\ maturation\\,\\ and\\ activity\\.\\ \\ \ \(0\)\
\-\ plain\\ film\\ radiograph\\ skeletal\\ survey\\ is\\ the\\ preferred\\ diagnostic\\ modality\\ for\\ the\\ detection\\ of\\ bony\\ involvement\\ in\\ mm\\.\\ \\ nearly\\ 50\\%\\ of\\ the\\ density\\ of\\ bone\\ must\\ be\\ affected\\ before\\ the\\ \\"punched\\-out\\"\\ lesions\\ are\\ apparent\\,\\ however\\,\\ the\\ presence\\ of\\ bone\\ lesions\\ is\\ confirmed\\ in\\ 60\\-80\\%\\ of\\ all\\ patients\\ initially\\ surveyed\\ for\\ mm\\ with\\ radiograph\\.\\ \\ other\\ useful\\ imaging\\ studies\\ include\\ mri\\,\\ which\\ may\\ be\\ used\\ for\\ the\\ precise\\ determination\\ of\\ lesion\\ size\\ and\\ location\\ for\\ bone\\ marrow\\ biopsy\\,\\ targeted\\ radiotherapy\\,\\ and\\ for\\ characterization\\ of\\ the\\ extent\\ of\\ disease\\.\\ \\ imaging\\ via\\ ct\\ is\\ adjunctive\\ to\\ mri\\ for\\ guided\\ biopsy\\ of\\ lesions\\.\\ \\ recently\\,\\ pet\\ scanning\\ has\\ shown\\ promise\\ for\\ monitoring\\ disease\\ recurrence\\ by\\ detection\\ of\\ lesions\\ not\\ readily\\ seen\\ on\\ conventional\\ radiograph\\.\\ \\ \ \(0\)\
\-\ due\\ to\\ the\\ osteolytic\\ nature\\ of\\ mm\\,\\ nuclear\\ imaging\\ via\\ technec\\ tium\\-99m\\ \\(tc\\-99m\\)\\ bone\\ scanning\\ has\\ no\\ role\\ in\\ diagnosis\\ or\\ monitoring\\.\\ \\ the\\ sensitivity\\ of\\ tc\\-99m\\ scanning\\ is\\ dependent\\ on\\ osteoblastic\\ activity\\,\\ and\\ therefore\\,\\ underestimates\\ the\\ extent\\ of\\ disease\\.\\ \\ uptake\\ of\\ tc\\-99m\\ into\\ radiographically\\ abnormal\\ regions\\ is\\ only\\ 44\\%\\ compared\\ to\\ conventional\\ plain\\ film\\.\\ \\ this\\ uptake\\ is\\ secondary\\ to\\ osteoblastic\\ activity\\ from\\ pathological\\ fracture\\,\\ calcification\\ within\\ a\\ plasmacytoma\\,\\ or\\ amyloidosis\\ in\\ association\\ with\\ tumor\\.\\ \\ \ \(0\)\
\-\ the\\ presence\\ of\\ osteolytic\\ lesions\\ is\\ not\\ pathognomonic\\ of\\ mm\\,\\ as\\ such\\ findings\\ may\\ be\\ present\\ in\\ a\\ variety\\ of\\ conditions\\ including\\ other\\ osteolytic\\ metastases\\ \\ and\\ occasionally\\ lymphoma\\)\\ and\\ hyperparathyroidism\\ \\ furthermore\\,\\ bilateral\\ lacrimal\\ gland\\ enlargement\\ with\\ homogenous\\ soft\\ tissue\\ attenuation\\ seen\\ on\\ ct\\ is\\ more\\ suggestive\\ of\\ lacrimal\\ gland\\ sarcoidosis\\ than\\ other\\ etiologies\\.\\ \\ neoplastic\\ and\\ infectious\\ processes\\ tend\\ to\\ present\\ with\\ discrete\\ lesions\\ within\\ the\\ lacrimal\\ gland\\ and\\/or\\ are\\ likely\\ unilateral\\.\\ \\ the\\ chronicity\\ of\\ symptoms\\ also\\ would\\ argue\\ against\\ a\\ bilateral\\ infection\\,\\ as\\ such\\ a\\ condition\\ would\\ be\\ likely\\ self\\-limiting\\.\\ \\ the\\ apparent\\ overlap\\ of\\ expected\\ findings\\ in\\ sarcoidosis\\ versus\\ that\\ of\\ mm\\ likely\\ contributed\\ to\\ the\\ lag\\ between\\ initial\\ presentation\\ and\\ diagnosis\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lacrimal\\:\\ 0\\.05555881766503587\ \(0\)\
\-\ mm\\:\\ 0\\.04249587721998019\ \(0\)\
\-\ gland\\:\\ 0\\.03763865790620899\ \(0\)\
\-\ sarcoidosis\\:\\ 0\\.027635021716218885\ \(0\)\
\-\ osteolytic\\:\\ 0\\.027546520220730668\ \(0\)\
\-\ myeloma\\:\\ 0\\.019750878370152904\ \(0\)\
\-\ biopsy\\:\\ 0\\.019294785945182247\ \(0\)\
\-\ punched\\-out\\:\\ 0\\.017730845018726987\ \(0\)\
\-\ diagnosed\\:\\ 0\\.017498302384697725\ \(0\)\
\-\ she\\:\\ 0\\.01717507977174825\ \(0\)\
\-\ amyloidosis\\:\\ 0\\.017023969836648438\ \(0\)\
\-\ bilateral\\:\\ 0\\.016498152182294702\ \(0\)\
\-\ monoclonal\\:\\ 0\\.015795450707948158\ \(0\)\
\-\ her\\:\\ 0\\.014308577254888266\ \(0\)\
\-\ tunnel\\:\\ 0\\.014012122779952407\ \(0\)\
\-\ plasma\\:\\ 0\\.013773260110365334\ \(0\)\
\-\ bone\\:\\ 0\\.013514301870866316\ \(0\)\
\-\ enlargement\\:\\ 0\\.013486747838047318\ \(0\)\
\-\ lesions\\:\\ 0\\.012739000433100743\ \(0\)\
\-\ \\,\\:\\ 0\\.012490997454258287\ \(0\)\
\-\ scanning\\:\\ 0\\.012486872280454388\ \(0\)\
\-\ patients\\:\\ 0\\.01231584900203833\ \(0\)\
\-\ lucencies\\:\\ 0\\.012235415202512081\ \(0\)\
\-\ carpal\\:\\ 0\\.012062812191582185\ \(0\)\
\-\ end\\-organ\\:\\ 0\\.011820563345817992\ \(0\)\
\-\ sinusitis\\:\\ 0\\.011800280222096915\ \(0\)\
\-\ via\\:\\ 0\\.011672311685451218\ \(0\)\
\-\ tc\\-99m\\:\\ 0\\.011655591387212822\ \(0\)\
\-\ \\%\\:\\ 0\\.01110043534878445\ \(0\)\
\-\ conjunctivitis\\:\\ 0\\.010930164319667757\ \(0\)\
\-\ 46\\:\\ 0\\.01079966344347997\ \(0\)\
\-\ protein\\:\\ 0\\.010464681682871561\ \(0\)\
\-\ conjunctival\\:\\ 0\\.010362662420003903\ \(0\)\
\-\ findings\\:\\ 0\\.01012876575221139\ \(0\)\
\-\ for\\:\\ 0\\.009860651174961143\ \(0\)\
\-\ is\\:\\ 0\\.009841206940703232\ \(0\)\
\-\ uri\\:\\ 0\\.009614844394155476\ \(0\)\
\-\ imaging\\:\\ 0\\.009556438302890706\ \(0\)\
\-\ presentation\\:\\ 0\\.009366430022246882\ \(0\)\
\-\ diagnosis\\:\\ 0\\.009366202056231121\ \(0\)\
\-\ lack\\:\\ 0\\.009279868111716692\ \(0\)\
\-\ plasmacytoma\\:\\ 0\\.009259802944172646\ \(0\)\
\-\ hypercalcemia\\:\\ 0\\.00910815588004484\ \(0\)\
\-\ appearing\\:\\ 0\\.009065008561220939\ \(0\)\
\-\ by\\:\\ 0\\.009055662073157517\ \(0\)\
\-\ staining\\:\\ 0\\.009037429129733252\ \(0\)\
\-\ marrow\\:\\ 0\\.008972011022955109\ \(0\)\
\-\ round\\:\\ 0\\.008810392469124677\ \(0\)\
\-\ osteoblastic\\:\\ 0\\.008724445368005242\ \(0\)\
\-\ suggestive\\:\\ 0\\.008712965274565596\ \(0\)\
\-\ survey\\:\\ 0\\.008369403918022409\ \(0\)\
\-\ initially\\:\\ 0\\.008300669079391839\ \(0\)\
\-\ that\\:\\ 0\\.008219463086644204\ \(0\)\
\-\ attenuation\\:\\ 0\\.008199572960444006\ \(0\)\
\-\ cells\\:\\ 0\\.00817767707434367\ \(0\)\
\-\ homogenous\\:\\ 0\\.008079313931078965\ \(0\)\
\-\ sequelae\\:\\ 0\\.008079313931078965\ \(0\)\
\-\ years\\:\\ 0\\.007984862806741393\ \(0\)\
\-\ detection\\:\\ 0\\.007900351348061161\ \(0\)\
\-\ radiological\\:\\ 0\\.007866853481397944\ \(0\)\
\-\ discrete\\:\\ 0\\.007834046341855007\ \(0\)\
\-\ based\\:\\ 0\\.00777730396722425\ \(0\)\
\-\ conventional\\:\\ 0\\.007709190947357799\ \(0\)\
\-\ has\\:\\ 0\\.00765966573028295\ \(0\)\
\-\ activity\\:\\ 0\\.007651662598523959\ \(0\)\
\-\ studies\\:\\ 0\\.007616947297802291\ \(0\)\
\-\ laboratory\\:\\ 0\\.007515732066477485\ \(0\)\
\-\ notable\\:\\ 0\\.007511812031415112\ \(0\)\
\-\ monitoring\\:\\ 0\\.007511812031415112\ \(0\)\
\-\ on\\:\\ 0\\.007486541893994085\ \(0\)\
\-\ nearly\\:\\ 0\\.007485512426083035\ \(0\)\
\-\ maxillary\\:\\ 0\\.00743418249415269\ \(0\)\
\-\ presence\\:\\ 0\\.007402829638322504\ \(0\)\
\-\ i\\.e\\:\\ 0\\.007266544442191152\ \(0\)\
\-\ damage\\:\\ 0\\.007266544442191152\ \(0\)\
\-\ multiple\\:\\ 0\\.007159132869845939\ \(0\)\
\-\ hyperparathyroidism\\:\\ 0\\.007135696234972422\ \(0\)\
\-\ lucenies\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ extremity\\-single\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ pa\\-chest\\-single\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ skull\\-numerous\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ terminally\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ demographically\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ outnumbering\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ 1\\.4\\-1\\.\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ 55\\-61\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ pauci\\-cellular\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ apple\\-green\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ congo\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ myelomatous\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ chemokine\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ chemotaxis\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ surveyed\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ technec\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ tium\\-99m\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ underestimates\\:\\ 0\\.007013141148740253\ \(0\)\
\-\ symptoms\\:\\ 0\\.0067769529893337765\ \(0\)\
\-\ extent\\:\\ 0\\.006747505879814026\ \(0\)\
\-\ skeletal\\:\\ 0\\.0067150335303610325\ \(0\)\
\-\ in\\:\\ 0\\.006704808753226013\ \(0\)\
\-\ disease\\:\\ 0\\.006667004970003361\ \(0\)\
\-\ ct\\:\\ 0\\.006656424481896819\ \(0\)\
\-\ unusual\\:\\ 0\\.006576590607545392\ \(0\)\
\-\ urine\\:\\ 0\\.006561926080727693\ \(0\)\
\-\ radiograph\\:\\ 0\\.006496297503392274\ \(0\)\
\-\ are\\:\\ 0\\.0064869666727981005\ \(0\)\
\-\ 5\\-9\\:\\ 0\\.0064617114108246245\ \(0\)\
\-\ thirteen\\:\\ 0\\.0064617114108246245\ \(0\)\
\-\ sometime\\:\\ 0\\.0064617114108246245\ \(0\)\
\-\ birefringence\\:\\ 0\\.0064617114108246245\ \(0\)\
\-\ mediated\\:\\ 0\\.0064617114108246245\ \(0\)\
\-\ argue\\:\\ 0\\.0064617114108246245\ \(0\)\
\-\ \\;\\:\\ 0\\.00644525437852854\ \(0\)\
\-\ therefore\\:\\ 0\\.006422267193086665\ \(0\)\
\-\ the\\:\\ 0\\.006379044162935796\ \(0\)\
\-\ form\\:\\ 0\\.006356780999779573\ \(0\)\
\-\ other\\:\\ 0\\.006267743989506599\ \(0\)\
\-\ lucency\\:\\ 0\\.006245297208822187\ \(0\)\
\-\ \\)\\:\\ 0\\.006244164370124388\ \(0\)\
\-\ age\\:\\ 0\\.006207423211322927\ \(0\)\
\-\ diffuse\\:\\ 0\\.006174242053401707\ \(0\)\
\-\ opthalmology\\:\\ 0\\.006139145692361486\ \(0\)\
\-\ eosinophillic\\:\\ 0\\.006139145692361486\ \(0\)\
\-\ osteoclast\\:\\ 0\\.006139145692361486\ \(0\)\
\-\ only\\:\\ 0\\.006132247394952114\ \(0\)\
\-\ of\\:\\ 0\\.006024460661789377\ \(0\)\
\-\ apparent\\:\\ 0\\.006012037902232092\ \(0\)\
\-\ per\\:\\ 0\\.005951224516678873\ \(0\)\
\-\ mulitple\\:\\ 0\\.005910281672908996\ \(0\)\
\-\ self\\-limiting\\:\\ 0\\.005910281672908996\ \(0\)\
\-\ complaints\\:\\ 0\\.005902264041473218\ \(0\)\
\-\ syndrome\\:\\ 0\\.005832712593638763\ \(0\)\
\-\ abnormal\\:\\ 0\\.005816449260894777\ \(0\)\
\-\ head\\:\\ 0\\.005784251337885194\ \(0\)\
\-\ characteristic\\:\\ 0\\.005755006193636711\ \(0\)\
\-\ likely\\:\\ 0\\.005752482018939515\ \(0\)\
\-\ and\\/or\\:\\ 0\\.005746239835942248\ \(0\)\
\-\ promise\\:\\ 0\\.00573276094791758\ \(0\)\
\-\ inflamatory\\:\\ 0\\.0055877159544458575\ \(0\)\
\-\ spike\\:\\ 0\\.0055877159544458575\ \(0\)\
\-\ electrophoresis\\:\\ 0\\.0055877159544458575\ \(0\)\
\-\ 60\\-80\\:\\ 0\\.0055877159544458575\ \(0\)\
\-\ targeted\\:\\ 0\\.0055877159544458575\ \(0\)\
\-\ been\\:\\ 0\\.005548436490367521\ \(0\)\
\-\ was\\:\\ 0\\.005503534332136681\ \(0\)\
\-\ hematology\\/oncology\\:\\ 0\\.005465082159833878\ \(0\)\
\-\ maintains\\:\\ 0\\.005465082159833878\ \(0\)\
\-\ maturation\\:\\ 0\\.005465082159833878\ \(0\)\
\-\ adjunctive\\:\\ 0\\.005465082159833878\ \(0\)\
\-\ uptake\\:\\ 0\\.005401723826084666\ \(0\)\
\-\ currently\\:\\ 0\\.005387705322214889\ \(0\)\
\-\ also\\:\\ 0\\.005360762430135725\ \(0\)\
\-\ punched\\:\\ 0\\.005358851934993367\ \(0\)\
\-\ exhibiting\\:\\ 0\\.005358851934993367\ \(0\)\
\-\ investigations\\:\\ 0\\.005358851934993367\ \(0\)\
\-\ coalesce\\:\\ 0\\.00526515023598272\ \(0\)\
\-\ stimulate\\:\\ 0\\.00526515023598272\ \(0\)\
\-\ overlap\\:\\ 0\\.00526515023598272\ \(0\)\
\-\ film\\:\\ 0\\.005222162188128843\ \(0\)\
\-\ 100\\,000\\:\\ 0\\.0051813312100019515\ \(0\)\
\-\ chronicity\\:\\ 0\\.0051813312100019515\ \(0\)\
\-\ indeed\\:\\ 0\\.005105507677938049\ \(0\)\
\-\ lag\\:\\ 0\\.005105507677938049\ \(0\)\
\-\ secretion\\:\\ 0\\.005036286216530229\ \(0\)\
\-\ precise\\:\\ 0\\.005036286216530229\ \(0\)\
\-\ determination\\:\\ 0\\.005036286216530229\ \(0\)\
\-\ year\\-old\\:\\ 0\\.004994056677324132\ \(0\)\
\-\ abnormalities\\:\\ 0\\.004994056677324132\ \(0\)\
\-\ involvement\\:\\ 0\\.004983195953266216\ \(0\)\
\-\ characterization\\:\\ 0\\.004972608644793128\ \(0\)\
\-\ sinus\\:\\ 0\\.004972408861801811\ \(0\)\
\-\ reported\\:\\ 0\\.004956364121839001\ \(0\)\
\-\ conclusion\\:\\ 0\\.00491365242191825\ \(0\)\
\-\ sought\\:\\ 0\\.00491365242191825\ \(0\)\
\-\ osteolysis\\:\\ 0\\.00491365242191825\ \(0\)\
\-\ and\\:\\ 0\\.004868978675334468\ \(0\)\
\-\ would\\:\\ 0\\.004838451676089244\ \(0\)\
\-\ tissue\\:\\ 0\\.004833940783896405\ \(0\)\
\-\ obtained\\:\\ 0\\.004833518060053846\ \(0\)\
\-\ or\\:\\ 0\\.004780538181211015\ \(0\)\
\-\ specimens\\:\\ 0\\.004759192585449708\ \(0\)\
\-\ contributed\\:\\ 0\\.004759192585449708\ \(0\)\
\-\ a\\:\\ 0\\.004732694532441542\ \(0\)\
\-\ most\\:\\ 0\\.004708437092429776\ \(0\)\
\-\ vertex\\:\\ 0\\.004670707593317469\ \(0\)\
\-\ ranging\\:\\ 0\\.004670707593317469\ \(0\)\
\-\ tuberosity\\:\\ 0\\.004670707593317469\ \(0\)\
\-\ elevated\\:\\ 0\\.004613072969545049\ \(0\)\
\-\ present\\:\\ 0\\.0046062261430350375\ \(0\)\
\-\ although\\:\\ 0\\.004591772920567389\ \(0\)\
\-\ appendicular\\:\\ 0\\.004591086703455111\ \(0\)\
\-\ readily\\:\\ 0\\.004591086703455111\ \(0\)\
\-\ size\\:\\ 0\\.004558275053904171\ \(0\)\
\-\ cardiopulmonary\\:\\ 0\\.00455407794002242\ \(0\)\
\-\ genitourinary\\:\\ 0\\.00455407794002242\ \(0\)\
\-\ cases\\:\\ 0\\.00452953200315216\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.004525467914361234\ \(0\)\
\-\ newly\\:\\ 0\\.004518714564866626\ \(0\)\
\-\ initial\\:\\ 0\\.004505301739505661\ \(0\)\
\-\ \\:\\:\\ 0\\.004495922100201531\ \(0\)\
\-\ constitutional\\:\\ 0\\.0044848564786146\ \(0\)\
\-\ feature\\:\\ 0\\.0044848564786146\ \(0\)\
\-\ may\\:\\ 0\\.004473337395938243\ \(0\)\
\-\ paresthesias\\:\\ 0\\.0044523807470949065\ \(0\)\
\-\ orbits\\:\\ 0\\.004421178906877499\ \(0\)\
\-\ plain\\:\\ 0\\.0044156940536023625\ \(0\)\
\-\ african\\-american\\:\\ 0\\.004391154779603953\ \(0\)\
\-\ manifestation\\:\\ 0\\.004391154779603953\ \(0\)\
\-\ demonstration\\:\\ 0\\.004391154779603953\ \(0\)\
\-\ amyloid\\:\\ 0\\.004391154779603953\ \(0\)\
\-\ malignancies\\:\\ 0\\.00433430596179795\ \(0\)\
\-\ further\\:\\ 0\\.004323697918536608\ \(0\)\
\-\ past\\:\\ 0\\.004320126447011033\ \(0\)\
\-\ consisting\\:\\ 0\\.004281249975721044\ \(0\)\
\-\ such\\:\\ 0\\.004250330612316392\ \(0\)\
\-\ b\\-cell\\:\\ 0\\.004231512221559282\ \(0\)\
\-\ prompted\\:\\ 0\\.004231512221559282\ \(0\)\
\-\ be\\:\\ 0\\.004193338817323562\ \(0\)\
\-\ bronchoscopy\\:\\ 0\\.0041847019590112045\ \(0\)\
\-\ united\\:\\ 0\\.0041847019590112045\ \(0\)\
\-\ attention\\:\\ 0\\.0041847019590112045\ \(0\)\
\-\ plan\\:\\ 0\\.0041622907601514625\ \(0\)\
\-\ skeleton\\:\\ 0\\.0041622907601514625\ \(0\)\
\-\ furthermore\\:\\ 0\\.0041622907601514625\ \(0\)\
\-\ during\\:\\ 0\\.00416071479701481\ \(0\)\
\-\ subcortical\\:\\ 0\\.004140493644647791\ \(0\)\
\-\ radiotherapy\\:\\ 0\\.004140493644647791\ \(0\)\
\-\ guided\\:\\ 0\\.004140493644647791\ \(0\)\
\-\ clavicle\\:\\ 0\\.00411927785540184\ \(0\)\
\-\ proliferation\\:\\ 0\\.0040986131884143615\ \(0\)\
\-\ proximal\\:\\ 0\\.004082009835651576\ \(0\)\
\-\ confirmation\\:\\ 0\\.004078471734170693\ \(0\)\
\-\ specimen\\:\\ 0\\.004078471734170693\ \(0\)\
\-\ infiltrate\\:\\ 0\\.0040396569655394825\ \(0\)\
\-\ preferred\\:\\ 0\\.0040396569655394825\ \(0\)\
\-\ seen\\:\\ 0\\.004030137506128139\ \(0\)\
\-\ \\(\\:\\ 0\\.004022698555057299\ \(0\)\
\-\ sclerosing\\:\\ 0\\.004020937397194062\ \(0\)\
\-\ role\\:\\ 0\\.004020937397194062\ \(0\)\
\-\ variety\\:\\ 0\\.004020937397194062\ \(0\)\
\-\ elderly\\:\\ 0\\.0040026482021067915\ \(0\)\
\-\ 3\\-4\\:\\ 0\\.003984770035160047\ \(0\)\
\-\ younger\\:\\ 0\\.003967284826950997\ \(0\)\
\-\ ultimately\\:\\ 0\\.003967284826950997\ \(0\)\
\-\ pathological\\:\\ 0\\.003967284826950997\ \(0\)\
\-\ osteopenia\\:\\ 0\\.003950175674030581\ \(0\)\
\-\ evaluation\\:\\ 0\\.003949465068936846\ \(0\)\
\-\ median\\:\\ 0\\.003933426740698972\ \(0\)\
\-\ not\\:\\ 0\\.003929415025431775\ \(0\)\
\-\ black\\:\\ 0\\.0039170231709275034\ \(0\)\
\-\ males\\:\\ 0\\.0039170231709275034\ \(0\)\
\-\ take\\:\\ 0\\.0039009510091792777\ \(0\)\
\-\ within\\:\\ 0\\.0038905284209691687\ \(0\)\
\-\ creatinine\\:\\ 0\\.00386974916896187\ \(0\)\
\-\ tend\\:\\ 0\\.0038545954736788996\ \(0\)\
\-\ all\\:\\ 0\\.0038455425448389673\ \(0\)\
\-\ sensitivity\\:\\ 0\\.0038397250416883247\ \(0\)\
\-\ against\\:\\ 0\\.003810792946086992\ \(0\)\
\-\ year\\:\\ 0\\.003803123585015572\ \(0\)\
\-\ secondary\\:\\ 0\\.003801161442337005\ \(0\)\
\-\ deposition\\:\\ 0\\.003796712136938702\ \(0\)\
\-\ however\\:\\ 0\\.003785788473503692\ \(0\)\
\-\ females\\:\\ 0\\.0037828762238823225\ \(0\)\
\-\ affecting\\:\\ 0\\.0037828762238823225\ \(0\)\
\-\ strongly\\:\\ 0\\.0037828762238823225\ \(0\)\
\-\ etiologies\\:\\ 0\\.003769276833779458\ \(0\)\
\-\ radiographically\\:\\ 0\\.003755906015707556\ \(0\)\
\-\ history\\:\\ 0\\.0037556548534831615\ \(0\)\
\-\ modality\\:\\ 0\\.003729820237805415\ \(0\)\
\-\ months\\:\\ 0\\.0037135104131902426\ \(0\)\
\-\ remained\\:\\ 0\\.0037045627212464807\ \(0\)\
\-\ gastrointestinal\\:\\ 0\\.0037045627212464807\ \(0\)\
\-\ one\\:\\ 0\\.0036845368071768405\ \(0\)\
\-\ pathognomonic\\:\\ 0\\.0036800824836436537\ \(0\)\
\-\ processes\\:\\ 0\\.0036800824836436537\ \(0\)\
\-\ dependent\\:\\ 0\\.003668119176273296\ \(0\)\
\-\ differentiated\\:\\ 0\\.003633272221095576\ \(0\)\
\-\ fatigue\\:\\ 0\\.003633272221095576\ \(0\)\
\-\ systems\\:\\ 0\\.0036108610222358338\ \(0\)\
\-\ insufficiency\\:\\ 0\\.0036108610222358338\ \(0\)\
\-\ ulnar\\:\\ 0\\.0035783852907161403\ \(0\)\
\-\ occasionally\\:\\ 0\\.0035783852907161403\ \(0\)\
\-\ pet\\:\\ 0\\.003567848117486211\ \(0\)\
\-\ musculoskeletal\\:\\ 0\\.003557448689031674\ \(0\)\
\-\ population\\:\\ 0\\.0035471834504987327\ \(0\)\
\-\ red\\:\\ 0\\.0035471834504987327\ \(0\)\
\-\ useful\\:\\ 0\\.0035471834504987327\ \(0\)\
\-\ comparison\\:\\ 0\\.0035370489828953676\ \(0\)\
\-\ hands\\:\\ 0\\.0035171593232251864\ \(0\)\
\-\ particularly\\:\\ 0\\.003507397913048723\ \(0\)\
\-\ m\\:\\ 0\\.003507397913048723\ \(0\)\
\-\ nuclear\\:\\ 0\\.003507397913048723\ \(0\)\
\-\ humerus\\:\\ 0\\.00349775482591082\ \(0\)\
\-\ prior\\:\\ 0\\.0034910306638064655\ \(0\)\
\-\ 44\\:\\ 0\\.003488227227623854\ \(0\)\
\-\ neoplastic\\:\\ 0\\.003478812384627034\ \(0\)\
\-\ over\\:\\ 0\\.003461642943739002\ \(0\)\
\-\ response\\:\\ 0\\.003407254519342277\ \(0\)\
\-\ more\\:\\ 0\\.003400439632954919\ \(0\)\
\-\ suggests\\:\\ 0\\.003398745936114952\ \(0\)\
\-\ 32\\:\\ 0\\.003390327392494795\ \(0\)\
\-\ anemia\\:\\ 0\\.0033819970027833433\ \(0\)\
\-\ conditions\\:\\ 0\\.0033819970027833433\ \(0\)\
\-\ unilateral\\:\\ 0\\.003373752939907013\ \(0\)\
\-\ discovered\\:\\ 0\\.003349521271263649\ \(0\)\
\-\ six\\:\\ 0\\.0033416053358196014\ \(0\)\
\-\ physical\\:\\ 0\\.0033357283525556696\ \(0\)\
\-\ consistent\\:\\ 0\\.0033338079058571253\ \(0\)\
\-\ components\\:\\ 0\\.0033337673911553118\ \(0\)\
\-\ lab\\:\\ 0\\.0033260059154628977\ \(0\)\
\-\ 65\\:\\ 0\\.003318319431046242\ \(0\)\
\-\ soft\\:\\ 0\\.003310941549711297\ \(0\)\
\-\ expected\\:\\ 0\\.0033107065026324388\ \(0\)\
\-\ association\\:\\ 0\\.003303165735763271\ \(0\)\
\-\ granulomatous\\:\\ 0\\.0032809630403638464\ \(0\)\
\-\ serum\\:\\ 0\\.0032809630403638464\ \(0\)\
\-\ upper\\:\\ 0\\.0032809554580250093\ \(0\)\
\-\ represents\\:\\ 0\\.003266498188269025\ \(0\)\
\-\ 1\\:\\ 0\\.0032352050405086825\ \(0\)\
\-\ infections\\:\\ 0\\.0032314464859666938\ \(0\)\
\-\ versus\\:\\ 0\\.0032314464859666938\ \(0\)\
\-\ nature\\:\\ 0\\.0032178470958638293\ \(0\)\
\-\ states\\:\\ 0\\.003197874207135845\ \(0\)\
\-\ current\\:\\ 0\\.0031848321945855853\ \(0\)\
\-\ predominantly\\:\\ 0\\.0031848321945855853\ \(0\)\
\-\ recently\\:\\ 0\\.0031720005462722335\ \(0\)\
\-\ received\\:\\ 0\\.00315937258353851\ \(0\)\
\-\ much\\:\\ 0\\.0031469419408152953\ \(0\)\
\-\ complaint\\:\\ 0\\.0031407987060548255\ \(0\)\
\-\ mri\\:\\ 0\\.0031237483769524584\ \(0\)\
\-\ having\\:\\ 0\\.0031226486044110937\ \(0\)\
\-\ radial\\:\\ 0\\.0031166894383576667\ \(0\)\
\-\ incidence\\:\\ 0\\.0031166894383576667\ \(0\)\
\-\ regions\\:\\ 0\\.00311077457878128\ \(0\)\
\-\ must\\:\\ 0\\.0030990751775166058\ \(0\)\
\-\ as\\:\\ 0\\.003084910515260448\ \(0\)\
\-\ distribution\\:\\ 0\\.003059431284320205\ \(0\)\
\-\ this\\:\\ 0\\.0030585114186607257\ \(0\)\
\-\ to\\:\\ 0\\.003057766886226632\ \(0\)\
\-\ factors\\:\\ 0\\.0030539257609752775\ \(0\)\
\-\ numerous\\:\\ 0\\.0030484580765776947\ \(0\)\
\-\ department\\:\\ 0\\.0030484580765776947\ \(0\)\
\-\ material\\:\\ 0\\.003037634168816534\ \(0\)\
\-\ \\'s\\:\\ 0\\.002997687539167932\ \(0\)\
\-\ their\\:\\ 0\\.0029756122583394365\ \(0\)\
\-\ case\\:\\ 0\\.002974549614745061\ \(0\)\
\-\ recurrence\\:\\ 0\\.002965729585309558\ \(0\)\
\-\ young\\:\\ 0\\.002960833908639408\ \(0\)\
\-\ review\\:\\ 0\\.002946325087995191\ \(0\)\
\-\ pending\\:\\ 0\\.002941547025894784\ \(0\)\
\-\ affected\\:\\ 0\\.002941547025894784\ \(0\)\
\-\ provided\\:\\ 0\\.0029320761408460024\ \(0\)\
\-\ total\\:\\ 0\\.0029273826467114054\ \(0\)\
\-\ infectious\\:\\ 0\\.002922716680559935\ \(0\)\
\-\ intermittent\\:\\ 0\\.0029180779213628045\ \(0\)\
\-\ relatively\\:\\ 0\\.0029088807675035555\ \(0\)\
\-\ parietal\\:\\ 0\\.002904321758188532\ \(0\)\
\-\ metastases\\:\\ 0\\.002904321758188532\ \(0\)\
\-\ skull\\:\\ 0\\.0028952813774006914\ \(0\)\
\-\ described\\:\\ 0\\.0028952813774006914\ \(0\)\
\-\ inflammation\\:\\ 0\\.002890799422175349\ \(0\)\
\-\ etiology\\:\\ 0\\.0028775030968183554\ \(0\)\
\-\ before\\:\\ 0\\.0028775030968183554\ \(0\)\
\-\ compared\\:\\ 0\\.0028775030968183554\ \(0\)\
\-\ bones\\:\\ 0\\.002868760756662751\ \(0\)\
\-\ recurrent\\:\\ 0\\.002868760756662751\ \(0\)\
\-\ condition\\:\\ 0\\.002843095790697578\ \(0\)\
\-\ nodules\\:\\ 0\\.002818232987591688\ \(0\)\
\-\ presenting\\:\\ 0\\.0027707236521090925\ \(0\)\
\-\ at\\:\\ 0\\.002763157882653062\ \(0\)\
\-\ single\\:\\ 0\\.0027554974466908765\ \(0\)\
\-\ slightly\\:\\ 0\\.0027479922500056268\ \(0\)\
\-\ 25\\:\\ 0\\.0027479922500056268\ \(0\)\
\-\ shown\\:\\ 0\\.0027258923581145564\ \(0\)\
\-\ patient\\:\\ 0\\.002725829533544592\ \(0\)\
\-\ bony\\:\\ 0\\.002718660081502582\ \(0\)\
\-\ symptomatic\\:\\ 0\\.002700861913042333\ \(0\)\
\-\ diagnostic\\:\\ 0\\.0026938526611074444\ \(0\)\
\-\ hypertension\\:\\ 0\\.0026800167480510646\ \(0\)\
\-\ similar\\:\\ 0\\.002666417357948201\ \(0\)\
\-\ rare\\:\\ 0\\.0026398967372102595\ \(0\)\
\-\ malignancy\\:\\ 0\\.0026269607619741576\ \(0\)\
\-\ used\\:\\ 0\\.0026079428456228814\ \(0\)\
\-\ 50\\:\\ 0\\.0025863150490404176\ \(0\)\
\-\ incidental\\:\\ 0\\.002574215272856226\ \(0\)\
\-\ emergency\\:\\ 0\\.002574215272856226\ \(0\)\
\-\ commonly\\:\\ 0\\.002565259700442038\ \(0\)\
\-\ course\\:\\ 0\\.002565259700442038\ \(0\)\
\-\ management\\:\\ 0\\.002565259700442038\ \(0\)\
\-\ confirmed\\:\\ 0\\.002556403821071438\ \(0\)\
\-\ which\\:\\ 0\\.0025380184363445486\ \(0\)\
\-\ since\\:\\ 0\\.002497028338662066\ \(0\)\
\-\ above\\:\\ 0\\.002491597976633108\ \(0\)\
\-\ extremity\\:\\ 0\\.0024862044309009053\ \(0\)\
\-\ calcification\\:\\ 0\\.0024676098794408348\ \(0\)\
\-\ malignant\\:\\ 0\\.0024571763535237083\ \(0\)\
\-\ including\\:\\ 0\\.002454589213200417\ \(0\)\
\-\ nerve\\:\\ 0\\.0024494400369827417\ \(0\)\
\-\ identified\\:\\ 0\\.002429170279384504\ \(0\)\
\-\ typically\\:\\ 0\\.0023997022828209803\ \(0\)\
\-\ location\\:\\ 0\\.0023712869426443066\ \(0\)\
\-\ being\\:\\ 0\\.0023689641820211285\ \(0\)\
\-\ given\\:\\ 0\\.0023304808214131604\ \(0\)\
\-\ now\\:\\ 0\\.0023238787507570786\ \(0\)\
\-\ asymptomatic\\:\\ 0\\.0022980050898934665\ \(0\)\
\-\ three\\:\\ 0\\.0022916660527819493\ \(0\)\
\-\ 10\\:\\ 0\\.0022916660527819493\ \(0\)\
\-\ recent\\:\\ 0\\.002285377127159743\ \(0\)\
\-\ left\\:\\ 0\\.002281874151009343\ \(0\)\
\-\ followed\\:\\ 0\\.0022791375269520854\ \(0\)\
\-\ swelling\\:\\ 0\\.00226476600157608\ \(0\)\
\-\ \\>\\:\\ 0\\.002258685373642454\ \(0\)\
\-\ out\\:\\ 0\\.0022466617954323915\ \(0\)\
\-\ density\\:\\ 0\\.0022367791224025134\ \(0\)\
\-\ bilaterally\\:\\ 0\\.0022328601738455874\ \(0\)\
\-\ showed\\:\\ 0\\.002228960435897929\ \(0\)\
\-\ finding\\:\\ 0\\.002190979717612157\ \(0\)\
\-\ several\\:\\ 0\\.002185435827941438\ \(0\)\
\-\ between\\:\\ 0\\.00215472994130807\ \(0\)\
\-\ radiographs\\:\\ 0\\.0021529600964217445\ \(0\)\
\-\ right\\:\\ 0\\.002151865654201472\ \(0\)\
\-\ found\\:\\ 0\\.0021424229231918157\ \(0\)\
\-\ frontal\\:\\ 0\\.002135474888212695\ \(0\)\
\-\ will\\:\\ 0\\.002126874318519604\ \(0\)\
\-\ medical\\:\\ 0\\.002091734128930791\ \(0\)\
\-\ no\\:\\ 0\\.0020535659921331792\ \(0\)\
\-\ renal\\:\\ 0\\.0020425422032283765\ \(0\)\
\-\ treated\\:\\ 0\\.002034885311124789\ \(0\)\
\-\ negative\\:\\ 0\\.002030326301809765\ \(0\)\
\-\ from\\:\\ 0\\.002015013067866686\ \(0\)\
\-\ demonstrated\\:\\ 0\\.0019947653002839838\ \(0\)\
\-\ infection\\:\\ 0\\.001976146836971207\ \(0\)\
\-\ with\\:\\ 0\\.0019547237055590173\ \(0\)\
\-\ lymphoma\\:\\ 0\\.0019428787863082623\ \(0\)\
\-\ axial\\:\\ 0\\.0019401682387174793\ \(0\)\
\-\ through\\:\\ 0\\.0019307533957206593\ \(0\)\
\-\ carcinoma\\:\\ 0\\.0019267523230038716\ \(0\)\
\-\ region\\:\\ 0\\.0019201282635157618\ \(0\)\
\-\ time\\:\\ 0\\.0019201282635157618\ \(0\)\
\-\ include\\:\\ 0\\.001907043347677237\ \(0\)\
\-\ an\\:\\ 0\\.0018801350267060141\ \(0\)\
\-\ blood\\:\\ 0\\.0018555378460694508\ \(0\)\
\-\ cell\\:\\ 0\\.0018363092375349931\ \(0\)\
\-\ significant\\:\\ 0\\.0018280406929627872\ \(0\)\
\-\ therapy\\:\\ 0\\.0018175344441054998\ \(0\)\
\-\ due\\:\\ 0\\.0018140629697317738\ \(0\)\
\-\ fracture\\:\\ 0\\.0017924219015694341\ \(0\)\
\-\ evidence\\:\\ 0\\.0017823727791303721\ \(0\)\
\-\ than\\:\\ 0\\.001781264005503798\ \(0\)\
\-\ common\\:\\ 0\\.0017790510834975316\ \(0\)\
\-\ who\\:\\ 0\\.0017724490128414496\ \(0\)\
\-\ both\\:\\ 0\\.001736038178747909\ \(0\)\
\-\ metastatic\\:\\ 0\\.0017113042192649884\ \(0\)\
\-\ \\`\\`\\:\\ 0\\.0016707518199139356\ \(0\)\
\-\ \\'\\'\\:\\ 0\\.0016386233110439483\ \(0\)\
\-\ into\\:\\ 0\\.0016176025202543412\ \(0\)\
\-\ noted\\:\\ 0\\.001611313594632135\ \(0\)\
\-\ associated\\:\\ 0\\.0016041866045407335\ \(0\)\
\-\ 3\\:\\ 0\\.001591865971922466\ \(0\)\
\-\ tumor\\:\\ 0\\.0015849103433658006\ \(0\)\
\-\ woman\\:\\ 0\\.0015703285182887084\ \(0\)\
\-\ posterior\\:\\ 0\\.0015669359973766498\ \(0\)\
\-\ demonstrate\\:\\ 0\\.0015644010670907247\ \(0\)\
\-\ it\\:\\ 0\\.001528121228745439\ \(0\)\
\-\ exam\\:\\ 0\\.001493423977684597\ \(0\)\
\-\ have\\:\\ 0\\.0014721066653660237\ \(0\)\
\-\ lateral\\:\\ 0\\.0014691074348643998\ \(0\)\
\-\ 2\\:\\ 0\\.0014638858365239032\ \(0\)\
\-\ but\\:\\ 0\\.0014498832943783116\ \(0\)\
\-\ female\\:\\ 0\\.0013975817593061526\ \(0\)\
\-\ presents\\:\\ 0\\.0013887385008018503\ \(0\)\
\-\ lesion\\:\\ 0\\.001384689917263687\ \(0\)\
\-\ treatment\\:\\ 0\\.0013759880346864654\ \(0\)\
\-\ \\.\\:\\ 0\\.0013555908772256335\ \(0\)\
\-\ pain\\:\\ 0\\.00083023720567282\ \(0\)\
